Fevipiprant in CRSwNP and comorbid asthma: Wrong target population or wrong PGD2 receptor? - 04/05/22
Doi : 10.1016/j.jaci.2022.03.001
Katherine N. Cahill, MD ⁎ 
Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, Tenn
∗Corresponding author: Katherine N. Cahill, MD, Vanderbilt University Medical Center, Division of Allergy, Pulmonary, and Critical Care Medicine, 1161 21st Ave S, Nashville, TN 37232.Vanderbilt University Medical CenterDivision of AllergyPulmonary, and Critical Care Medicine1161 21st Ave SNashvilleTN37232
Key words : Chronic rhinosinusitis with nasal polyposis, asthma, fevipiprant, prostaglandin D2, aspirin-exacerbated respiratory disease
Le texte complet de cet article est disponible en PDF.
| Disclosure of potential conflict of interest: K. N. Cahill has severed on scientific advisory boards for Teva, Novartis, GlaxoSmithKline, Blueprint Medicines, Regeneron, Genentech, and Sanofi, and she reports personal fees from Novartis, Third Harmonic Bio, Ribon Therapeutics, and Verantos, as well as funding from the National Institutes of Health (grants NIH U01AI155299 and U19AI095227) outside the submitted work. |
© 2022
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 149 - N° 5
P. 1587-1589 - mai 2022 Retour au numéro
Article précédent
- Understanding the highs and lows of socioeconomic status
- Elizabeth A. Erwin, Kelly J. Kelleher
- Atopic dermatitis and the atopic march: Considering racial and ethnic diversity in atopic disease progression
- Junko Takeshita, Jayanta Gupta, Yaqian Zhu, Ronald Berna, Zelma C. Chiesa Fuxench, David J. Margolis
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?